The restoration of the pharmacological sensitivity of the tumour cells is favored by the increase of NF-κB activity, confirming that HMGB1 regulates drug resistance in MM cells by regulating the NF-κB signalling pathway. Here, HMGB1 is linked to Miyoshi myopathy.